What question did this study set out to answer?

The research aims to clarify the clinical characteristics, treatment responses, and relapse patterns of advanced-stage high-grade B-cell lymphoma.

July 12, 2026Blood AdvancesOpen Access

Clinical outcomes, patterns of relapse and molecular landscape of advanced stage High Grade B-cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial examines clinical outcomes in advanced high grade B-cell lymphoma, suggesting new molecular insights.

The research aims to clarify the clinical characteristics, treatment responses, and relapse patterns of advanced-stage high-grade B-cell lymphoma.
Analyzed clinical data from 124 advanced-stage high-grade B-cell lymphoma cases treated at Memorial Sloan Kettering Cancer Center
Conducted targeted next-generation sequencing on 36 of these cases using MSK-IMPACT HEME
Compared outcomes based on different rearrangements: MYC/BCL2, MYC/BCL6, and MYC/BCL2/BCL6.
Overall survival at 2 years was 59.8% with complete response rates at 44%.
Identified high rates of CNS relapse at 10.1%, particularly in MYC/BCL6-R disease.
Patients with MYC/BCL6-R had increased risks of rapid progression and unique tumor characteristics compared to BCL2-R cases.

Healton et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark